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A method based on liquid chromatography-tandem mass spectrometry and microbore 
column separation was developed for the quantification of a potent 5-HT,, receptor antago- 
nist (RI-( + )-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine-methanol (I) 
and the desmethyl metabolite (II) in rat brain extracellular fluid (ECF) following microdialy- 
sis sampling. The analytical method was also applied to determining plasma concentrations 
of these compounds. The lower limit of quantification (LLQ) for each compound in micro- 
dialysis perfusate is 500 pg/mL, which translates to < 7 fmol (injected). The recovery of I and 
II for the microdialysis probe in brain ECF was 18.5 and 22.7%, respectively. The LLQ for 
each compound in plasma is 1 ng/mL. The inherent selectivity offered by tandem mass 
spectrometry eliminated chemical noise, thereby improving the detectability of these com- 
pounds. These methods were used to confirm that I and II penetrated the blood-brain barrier 
following administration of I to rats and enabled comparison of plasma and brain ECF 
concentrations. (J Am Sot Mass Spectrom 1997,8, 371-379) 0 1997 American Society for 
Mass Spectrometry 
M icrodialysis sampling of in vivo systems has emerged as a powerful tool for investigations of drug pharmacokinetics and metabolism 
[l-41. The initial development of microdialysis sam- 
pling was for probing brain neurochemistry, usually 
for the measurement of endogenous neurotransmitters 
[5-lo]. However, continued application of this tech- 
nique has proven its use in sampling many other 
tissues and organs including skin [ 111, muscle [ 12-141, 
adipose [15-171, liver [13, 18-201 and biological fluids 
[18, 21-231. Specific placement of the microdialysis 
probe within the organ or tissue accesses the extracel- 
lular fluid (ECF) for sampling small molecules, either 
endogenous compounds or drugs. Small molecules 
diffuse through the microdialysis membrane and are 
swept away by the perfusion medium, which ideally is 
prepared to match the ionic strength and pH of the 
extracellular space that is being sampled, thereby min- 
imizing changes in the microenvironment adjacent to 
the microdialysis probe [l]. Although insertion of the 
probe is invasive and will alter the physiochemical 
environment in the immediate area of implantation, it 
does not impact the integrity of the whole animal. 
Address reprint requests to Dr. Timothy G. Heath, Hoechst Marion 
Roussel Inc., P.O. Box 9627, Kansas City, MO 64134-0627. E-mail: 
timheath@hmri.com 
0 1997 American Society for Mass Spectrometry 
1044-0305/97/$17.00 
PI1 S1044-0305(96)00289-9 
Implantation of a microdialysis probe within tissue 
provides the capability of continuous sampling with- 
out the loss of fluids. This feature offers potentially 
greater temporal resolution than does serial sampling 
for monitoring drug concentrations, which is advanta- 
geous in pharmacokinetic and metabolism studies [3, 
18, 221. However, the inherent characteristics of micro- 
dialysis sampling present analytical challenges for 
measuring analyte concentration. Typically, to achieve 
the highest possible recovery of analytes from the 
matrix, the flow of the perfusion medium is 1 pL/min 
or less. To maintain the temporal resolution advantage 
requires the handling and subsequent analysis of a low 
volume sample that contains high salt concentrations 
and dilute analyte concentrations. Often, samples are 
analyzed by liquid chromatography (LC) with sensi- 
tive detection provided by electrochemical [5, 18, 
24-271, ultraviolet [18, 28-301, fluorescence [31], or 
mass spectrometry 13, 4, 7, 22, 23, 32-341. Capillary 
electrophoresis is well suited to the analysis of low 
sample volumes and is being increasingly utilized 
[7, 351. 
As a potent and selective 5-HT,, receptor antago- 
nist, MDL 100,907 [CR)-( + )-a-(2,3-dimethoxyphenyl)-l- 
[2-(4-fluorophenyl)ethyl]-4-piperidine-methanol, (I)], 
shown in Figure 1, has been proposed, depending on 
the brain region, to either reduce or increase dopamine 
production [36]. A drug with this capability may be 
Received July 25,1996 
Revised October 1,1996 
Accepted November 4,1996 
372 HEATH AND SCOT-I J Am Sot Mass Spectrom 1997,8,371-379 
scribes the analytical methodology that was used to 
investigate the pharmacokinetics of I in the rat central 
nervous system (CNS) and plasma. 
Experimental 
Comoound R M.W. 
I(R) - OCH3 313 
11 (RI -OH 359 
13. (RS) -H 343 
Figure 1. Structures of compounds I, II, and IS. 
useful as a novel therapy for schizophrenic patients. 
Schizophrenia is unique in that as a disorder there are 
what are termed positive symptoms and negative dis- 
orders due to excessive and reduced dopamine activity 
within different regions of the brain [9]. Treatment for 
schizophrenia usually involves administering neu- 
roleptics or typical antipsychotics, which are dopamine 
D, receptor antagonists. While attenuating the effects 
of the dopaminergic system, typical antipsychotics of- 
ten exhibit negative side effects. These side effects 
include those manifested in the form of drug-induced 
Parkinsonism, which account for bradykinesia, tremor, 
and rigidity. Such side effects therefore, often limit the 
use of typical antipsychotics. Antagonists of 5-HT,, 
receptors however, offer an alternative approach for 
reducing dopaminergic activity. Compound I exhibits 
300-lOOO-fold selectivity for 5-HT, receptors (Ki = 
0.36 nM) as compared to other neurotransmitter recep- 
tors (serotonin, 5-I-H,,; dopamine, D,; adrenergic, a~,), 
and has been shown to increase dopamine efflux in the 
medial prefrontal cortex (mPFC) of the rat brain [36] 
and decrease the activity of ventral tegmental area 
dopamine neurons [37]. The ability to regulate activity 
selectively via 5-HT.,, antagonism is a strategy being 
pursued for the development of novel medications for 
the treatment of schizophrenia [9, 361. 
Studies showing increased dopamine levels in the 
mPFC of the rat brain have previously been conducted 
after I was administered directly into the brain via the 
microdialysis probe [36]. In our studies, microdialysis 
sampling was used to obtain samples representative of 
the brain ECF following intravenous (i.v.) and oral 
administration of the drug to rats. A method based on 
liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) was developed which enabled the quan- 
tification of I and II in both brain ECF (via microdialy- 
Materials 
Compounds I and II and the internal standard (I.S.) 
(refer to Figure 1) were obtained from Hoe&t Marion 
Roussel Research Institute (Cincinnati, OH). Acetoni- 
trile was high performance liquid chromatography 
(HPLC) grade (Burdick and Jackson, Muskegon, MI). 
Water was purified through a NANOpure II system 
(Barnstead, Dubuque, IA) prior to use. Artificial cere- 
bral spinal fluid (aCSF) was used as the dialysis per- 
fusate and consisted of 2.5-n-M KCl, 1.18mM MgCl,, 
1.26~mM CaCl,, and 125-n-M NaCl. All reagents used 
in the preparation of buffer solutions were of analytical 
reagent grade or better. 
Instrumentation 
Chromatographic separations were performed with a 
Michrom BioResources Ultrafast Microprotein Ana- 
lyzer HPLC system (Michrom BioResources, Pleasan- 
ton, CA). Following chromatographic separation, 
0.127-mm-i.d. Polyetherether ketone (PEEK) tubing de- 
livered the effluent to the electrospray ionization source 
of a Finnigan MAT (San Jose, CA) TSQ 700 mass 
spectrometer via a Valco Instruments (Houston, TX) 
electric six port injector valve. This divert valve was 
installed to allow for automated control of the effluent 
flow to the mass spectrometer. The heated capillary 
was maintained at a temperature of 220 “C, and the 
nose cone needle was at 4.5 kV. Nitrogen was the 
sheath gas at a pressure of 38 lb/in.*. Collision-in- 
duced dissociation (CID) of the protonated molecules 
of the analytes (m/z 374.1, 360.1) and the internal 
standard (m/z 344.1) caused fragmentation within the 
second quadrupole collision cell (Q2). Argon was the 
collision gas in 42 at a pressure of 2.2 mtorr with a 
collision energy of 35 eV (Ebb). The product ion moni- 
tored by the third quadrupole (43) for both analytes 
and the internal standard was m/z 123 (kO.2 u; 0.5-s 
dwell time). The electron multiplier was set to 1600 V 
unless otherwise indicated. The samples were injected 
by a Gilson (Middleton, WI) model 231 autosampler. 
sis sampling) and plasma (samples serially collected). 
These experiments were performed to provide direct 
lsocra tic Chroma tographic Conditions 
evidence-as to the ability- of I and II to- penetrate the The mobile phase consisted of acetate buffer- 
blood-brain barrier (BBB). Plasma samples were ana- acetonitrile (42-58, v/v). The aqueous buffer was pre- 
lyzed to compare the concentrations of I and II in the pared by adding 10 mL of glacial acetic acid and 3.85 g 
brain ECF. Although the sample processing for the two of ammonium acetate to 990 mL of waier. The HPLC 
methods differed slightly, the selected reaction moni- column was an Alltima C8 (5 pm, 100 A, 150 X 1 mm 
toring (SRM) detection was identical. This report de- i.d.; Alltech, Deerfield, IL). The column was main- 
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tained at ambient temperature. The flow rate was 65 
pL/min. All the chromatograms shown in the figures 
were generated without the use of a data smoothing 
routine. 
Microdialysis 
Animal preparation. Surgical implantation of the mi- 
crodialysis probe (CMA/12, 2-mm probe length) con- 
sisting of a polycarbonate membrane (CMA/Microdi- 
alysis, Acton, MA) in the medial prefrontal cortex 
(mPFC) region of the rat brain was conducted as previ- 
ously described 1381. After insertion of the microdialy- 
sis probe, the animal was placed in a plexiglass con- 
tainment system (CMA/Microdialysis) and allowed to 
recover for 24 h prior to dosing with I. 
Dose preparation and administrarion. For i.v. adminis- 
tration, animals (n = 3) were given a 5-mg/mL solu- 
tion of I, which was prepared in a vehicle composed of 
2% (w/w> citric acid, 0.6% (w/w) sodium citrate, and 
0.5% (w/w) propylene glycol. A 50-mg/mL solution 
of I was prepared in 5.1% (w/w) citric acid, 1.6% 
(w/w> sodium citrate, and 41.4% (w/v) propylene 
glycol for oral administration in rats (n = 3). Fresh 
dosing solutions were prepared on each day of dosing. 
Sample collection. The microdialysis perfusate was de- 
livered via a syringe pump (CMA/Microdialysis) 
through the microdialysis probe at a rate of 1 FL/min. 
Dialysate samples were collected over lo-min intervals 
into 300-PL autosampler vials (Chromacol, Trumbull, 
CT) by using a CMA/170 refrigerated sample collector 
set at 5 “C. At the end of the study, dialysate samples 
were kept frozen at -20 “C until analysis. Blood sam- 
ples (- 100 pL/sample) were collected through the 
in-dwelling jugular vein cannula at 5 (i.v. dose only), 
15, 30, 60, 90, 120, 180, 240, and 360 min postdose. 
Samples were collected into 64 X 10.25~mm hep- 
arinized Vacutainer @ tubes (Becton Dickinson, 
Rutherford, NJ) and centrifuged at 3500 rpm (5 “C> for 
15 min. The resulting plasma was pipetted into I-mL 
microcentrifuge tubes and frozen at -20 “C until 
analysis. 
In vivo recovery deferminahon. Following insertion of 
the probe into the mPFC of the rat brain, the probe 
was perfused with aCSF at a flow rate of 1.0 pL/min. 
Prior to dosing with I, the in vivo delivery of the 
microdialysis probe was determined by perfusing the 
probe with a 50-ng/mL solution of I and II in aCSF. 
Delivery = (C, - Cout)/Cin, where C,, is the mea- 
sured concentration of analyte in the per&ate coming 
out of the probe whereas C, is the initial concentra- 
tion of the analyte within the perfusate. Assuming that 
in vivo recovery is equal to delivery [39], the in vivo 
recovery of the probe was then calculated by using the 
formula %recovery,, +,, = delivery X 100. 
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Sample Preparation 
Microdialysis perfusate samples. The only sample 
preparation required was the addition of 10 PL of I.S. 
solution to the collected perfusate sample (10 PL). The 
autosampler was programmed to draw 10 PL of I.S. 
solution (50 ng/mL) from a vial and introduce it into 
the vial containing 10 PL of perfusate. The subsequent 
sample was mixed with the syringe and a IO-PL aliquot 
was injected onto the chromatograph. Calibration stan- 
dards used for the calibration curve were prepared in 
aCSF that was fortified with I and II. These standards 
were prepared and analyzed at concentrations of 0.5,1, 
5, 10, 25, 100, 250, 500, and 1000 ng/mL. Ten micro- 
liters of each calibration standard were placed in the 
autosample vials (in duplicate) for the LC/MS-MS 
analysis. 
Rat plasma samples. To 25 PL of rat plasma was added 
50 PL of acetonitrile fortified with I.S. at 50 ng/mL. 
Following the precipitation of plasma proteins, the 
sample was centrifuged for 10 min at 3500 rpm and the 
resulting supernatant was added to the autosample 
vial. The calibration standards were prepared as before 
after fortifying drug-free rat plasma (Pel Freez Biologi- 
cals, Rogers, AK) with I and II. Replicate calibration 
standards were analyzed at 1, 5, 10, 25, 100, 250, and 
500 ng/mL. The injection volume onto the chromato- 
graphic column was 5 pL. The recovery of I, II, and I.S. 
from plasma following protein precipitation with ace- 
tonitrile was determined at 5, 50, and 500 ng/mL by 
comparing the peak areas of extracted plasma 
with the peak areas of identically treated 
aqueous samples. 
samples 
fortified 
Assay Validation 
The methods for analyzing both plasma samples and 
microdialysis perfusate samples were validated over 
the course of three days by the analysis of control 
samples at three concentration levels in the range of 
the calibration curve. Within-day reproducibility and 
accuracy was determined from the measurement of at 
least six replicates of quality control (QC) samples for 
perfusate samples and at least nine replicates for 
plasma samples. The between-day reproducibility was 
calculated by comparing three days of analyses run in 
replicates of greater than or equal to 6 on each day, for 
a total of at least 18 for the microdialysis perfusate 
samples and 24 for the plasma samples. The concentra- 
tions of QC samples prepared with the calibration 
standards and study samples were determined by us- 
ing the logarithmic regression analysis equation. 
Results and Discussion 
Mass Spectrometry Analysis 
To determine the mass spectrometric conditions that 
generated optimal detection of I and II, the analytes 
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were dissolved in mobile phase and continually in- 
fused into the ionization source of the mass spectrome- 
ter. Displayed in Figure 2 are the CID product ion 
mass spectra of the protonated molecules of I and II 
following the LC separation of 1 ng of each compound. 
For both analytes, the two major product ions were 
m/z 123 and 204. Proposed ion structures for the 
fragment ions of protonated compound I are depicted 
in Figure 2a. For those peaks labeled in each of the 
spectra with the same mass-to-charge ratio values, the 
structures of the ions are identical. The ion observed as 
a peak at m/z 232 for compound I shifts to an ion with 
m/z 218 for II. The fragmentation upon CID is cen- 
tered around the basic nitrogen of the piperidine moi- 
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Figure 2. Product ion mass spectrum of the protonated 
molecules of (a) I and (b) II following CID with argon at a 
pressure of 2.2 mtorr and collision energy of 35 eV (lab). 
ety. Whereas both compounds upon CID of [M + HI+ 
yielded intense ion current at m/z 123, it was antici- 
pated that the selectivity provided by SRM would 
minimize the required sample preparation and provide 
a low level of detection. Because both microdialysis 
perfusate and plasma samples were to be analyzed, an 
LC-MS/MS method was sought that would be identi- 
cal for the analysis of compounds in each matrix. This 
would enable concurrent analysis of each matrix with 
changes required only for the autosampler procedures. 
Selected Reaction Monitoring versus Selected 
Ion Monitoring 
The limit of detection CLOD) of an analytical method is 
indicated by the amount of material required to gener- 
ate a chromatographic peak with an acceptable signal- 
to-noise (S/N). Two strategies can be invoked in an 
attempt to improve the LOD. First, one can try to 
improve the sensitivity of a method by selecting a 
detector that produces the largest response per amount 
of compound introduced. A second approach is to 
minimize the chemical noise, thereby improving the 
specificity of the analytical method [40]. SRM virtually 
eliminates chemical noise. 
The suitability of this assay method for the analysis 
of perfusate samples is demonstrated in Figure 3, which 
shows the reconstructed ion chromatograms obtained 
from blank aCSF and aCSF fortified with I and II to a 
level of 1 ng/mL. The analysis of the l-ng/mL sample 
corresponds to less than 14 fmol injected. A chromato- 
graphic peak with S/N - 4 is detected for both com- 
pounds. Displayed in Figure 4 are data obtained in the 
analysis of a 50-ng/mL aCSF sample following SRM 
and selected ion monitoring (SIM) of the protonated 
molecule. The absolute intensity of the signal in the 
SIM mode is more than 10 times that of SRM. Similar 
detection limits could be achieved for I by using SRM 
or SIM; however, high background ion current of un- 
known origin with m/z 360 throughout the chromato- 
graphic analysis precluded low level detection of II by 
Figure 3. Chromatographic profiles obtained following the SRM 
analysis of blank aCSF (a) and (c) and aCSF fortified with I and II 
to 1 ng/mL (b) and cd). The arrows in panels a and c indicate 
where compounds I and II elute under these chromatographic 
conditions. 
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Figure 4. Chromatographic profiles obtained following the 
analysis of aCSF fortified with I and II. (a) and (c) were obtained 
following SRM analysis of aCSF fortified to 50 ng/mL, whereas 
(b) and (d) were obtained following SIM analysis of aCSF forti- 
fied to 50 ng/mL. The arrows in b and d indicate the time where 
the divert valve switched, directing effluent flow to the mass 
spectrometer. 
SIM. This is evident from Figure 4c and d in which the 
ion chromatograms for SRM and SIM analysis of 50- 
ng/mL aCSF are displayed. Although similar S/N 
values are observed for I in the two mass spectrometry 
approaches (Figure 4a and b), clearly, SRM is superior 
for the analysis of II (Figure 4c and d). This back- 
ground ion current of m/z 360 presumably is from a 
component found in the mobile phase as the ion cur- 
rent is quite constant. The chemical noise generated in 
the blank perfusate sample when analyzed by SRM is 
nearly identical for I and II (Figure 3a and c> because 
the additional selectivity offered by tandem mass spec- 
trometry eliminates the high background ion current 
detected at m/z 360 in the SIM analysis. 
It is of interest to deduce the source of the noise that 
is present in these analyses. The effect that increasing 
the electron multiplier voltage (EMV) has on the signal 
in either SIM or SRM mode helps define the noise as 
either chemical or electronic. Presumably, a majority of 
the background ion current generated in the SIM anal- 
ysis is due to chemical noise, that is, noise resulting 
from the mobile phase. Ions are formed in the ion 
source and impact the conversion dynode of the elec- 
tron multiplier. When the multiplier voltage is in- 
creased from 1000 to 1600 V, the background SIM ion 
current increases 75-100-fold (data not shown). 
The source of background ion current in the SRM 
analysis of plasma extracts does not appear to be 
primarily from chemical noise. The reconstructed ion 
chromatogram (m/z 374 --) 123) obtained in the SRM 
analysis of blank plasma extract with a multiplier 
setting of 1600 V is shown in Figure 5a. The chro- 
matogram obtained under identical conditions for the 
5-ng/mL plasma extract is shown in Figure 5b. This 
5-ng/mL plasma extract was reanalyzed with the EMV 
set to 1000 V as seen in Figure 5c. There is only an 
approximate fourfold decrease in the signal of back- 
ground ion current generated in the SRM analysis 
when the EMV is changed from 1600 to 1000 V as 
3:20 
-EM2 
P) 4.c!ilo 
g 400. 
S ng/mL plasma 
?I EMV: 1OOOV 
2 
B 
1:4O 230 3:20 
Retention time, minutes 
Figure 5. The SRM analysis of I in plasma extracts. (a) Blank 
extract, EMV at 1600 V; (b) 5-ng/mL extract, EMV at 1600 V; (c) 
5-ng/mL extract, EMV at 1000 V. Note the absolute scale for the 
ordinate of each chromatogram is the same (4 X lo*). 
demonstrated in Figure 5. However, the analyte re- 
sponse (ion event at dynode) is not detected when the 
EMV is set to 1000 V in the analysis of the 5-ng/mL 
extract. These data indicate that nearly all of the noise 
in the background of the SRM analysis is electronic 
noise generated within the components of the circuit 
following the electron multiplier, and not chemical 
noise. Because the primary source of the noise is after 
the electron multiplier, a minimal increase in the back- 
ground noise is observed when the EMV is increased, 
whereas there is a significant increase in detected sig- 
nal when analyte ions strike the conversion dynode 
prior to generating the electron cascade. 
Calibration Curves 
Calibration curves for both I and II were constructed 
after analyzing standards in at least duplicate. Loga- 
rithmic regression analysis of the reconstructed ion 
chromatogram peak area ratios versus analyte concen- 
tration were performed. The correlation coefficients of 
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the calibration curves for I and II in aCSF were typi- 
cally greater than 0.998. The correlation coefficients of 
the calibration curves for I in plasma were typically 
greater than 0.998, whereas for II in plasma, they were 
greater than 0.997. 
Extraction Efficiency in Rut Plasma 
For the analysis of I and II in rat plasma, the extraction 
efficiency (EE) of the protein precipitation with ace- 
tonitrile was determined at concentrations of 5,50, and 
500 ng/mL of each compound. Peak areas of triplicate 
extracted plasma standards were compared to peak 
areas of corresponding aqueous standards. The extrac- 
tion efficiency for compound I averaged 79%, whereas 
the extraction efficiencies for II and the I.S. averaged 37 
and 38%, respectively. Although all three compounds 
are structurally very similar, the recovery in plasma 
was significantly greater for I. We do not have an 
explanation for these observed differences in recovery. 
The data summarizing the extraction efficiency results 
are shown in Table 1. 
In Vivo Recovery in Brain Extracellular Fluid 
Calculation of the brain concentrations of both I and II 
were based on the in vivo recovery that was deter- 
mined after implanting the probe into the brain. Based 
Table 1. Extraction efficiency from rat plasma for I, II, and I.S. 
following protein precipitation with acetonitrile (n = 3) 
Concentration 
of I and II (ng/mL) 
5 
50 
500 
Extraction efficiency(%) 
I II 1.s.a 
69 35 35 
87 41 38 
81 34 41 
aThe internal standard concentration was 100 ng/mL for all 
concentrations of I and II. 
on the assumption that in vivo recovery is equal to in 
vivo delivery, which was determined in our experi- 
mental procedure [36], the recovery of I was 18.5%, 
whereas the recovery of II was 22.7%. 
Accuracy, Precision, and Lower Limit 
of Quantification 
The accuracy and precision of the method were deter- 
mined from the analysis of three sets of QC samples 
for both aCSF samples and rat plasma samples. These 
data are summarized in Tables 2 and 3. Generally, the 
percent relative standard deviation (RSD) and percent 
relative error (RE) determinations for compounds I 
and II were similar for the analysis of aCSF. The lower 
Table 2. Precision and accuracy data for determination of I and II in microdialysis perfksate 
Concentration Within-day (n 2 6) Between-day (n 2 18) 
(ng/mL) Found RSD= (%o) REb (%I Found RSDa (%I REb 1%) 
Compound I 
0.50 0.50 15.0 0.0 0.49 14.7 -2.0 
25 24.6 6.7 - 1.6 25.7 12.1 2.8 
250 268.9 7.4 7.6 276.8 6.8 10.7 
Compound II 
0.50 0.57 16.9 14.0 0.52 16.8 4.0 
25 23.8 10.9 -4.8 24.1 14.5 -3.6 
250 258.2 8.7 3.3 264.3 6.8 5.7 
aRelative standard deviation. 
bRelative error. 
Table 3. Precision and accuracy data for determination of I and II in rat plasma 
Concentration Within-day (n 2 9) Between-day (n 2 24) 
(ng/mL) Found RSDa (%I REb (%I Found RSDa (%I REb (%I 
Compound I 
5 5.9 1 1.4 18.0 5.4 14.4 8.0 
50 45.6 4.5 -8.8 51 .o 11.6 2.0 
500 541.5 2.5 8.3 532.0 5.5 6.4 
Compound II 
5 5.3 19.0 6.0 5.9 17.6 18.0 
50 47.9 19.5 -4.2 52.4 18.3 4.8 
500 443.9 5.9 -11.2 507.6 12.2 1.5 
aRelative standard deviation. 
bRelative error. 
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limit of quantification (LLQ) for each compound in 
aCSF was 500 pg/mL. The precision in the measure- 
ment of II in plasma as indicated by RSD was slightly 
inferior to that of I in plasma. This is attributed to the 
lower EE of II from plasma following acetonitrile pre- 
cipitation of plasma proteins. Variation in the recovery 
of II from sample to sample has a greater impact on 
RSD than it does in the case of I, which has a higher 
EE. Precision and accuracy data are shown in Table 3 
for 5 ng/mL in rat plasma, although 1 ng/mL was 
readily detected and was used as the low level calibra- 
tion standard. The RE and RSD for the I-ng/mL plasma 
calibration standards were typically N 20% for each 
compound so 1 ng/mL was considered as the LLQ. 
The high organic content of the plasma extract limited 
our injection volume to 5 pL; larger injection volumes 
caused unacceptable broadening in the chromate 
graphic peak shape. 
The reproducibility of the absolute signal of I.S. 
measured as peak area was used to assess the preci- 
sion of the microdialysis perfusate assay. This is useful 
in determining the effect that handling the small vol- 
ume samples has on the measurement of I and II in 
perfusate. Generating a microdialysis sample from a 
rat involves collection of IO-PL perfusate over a IO-mm 
period. The collection vials were capped and refriger- 
ated to minimize sample evaporation prior to analysis. 
For the analysis, a lo-PL aliquot of I.S. solution was 
added by the autosampler to the sample and then 
mixed. Finally, 10 PL of sample was injected onto the 
chromatograph. Any variability that occurs within each 
of these steps along with variability in the mass spec- 
trometer response will impact the signal generated for 
the IS. Therefore, the precision determined for the 
measurement of the I.S. signal from study samples 
reflects the overall precision of the analytical proce- 
dure. Displayed in Figure 6 is a graphical representa- 
tion of the precision of the experiment following the 
analysis of brain microdialysis perfusate samples col- 
lected from a rat that had been dosed with I. The I.S. 
peak areas for nearly all of the injections were within 
+ 10% of the mean. The decreases in the I.S. responses 
at injections numbers 19 and 20 may be due to a 
partially plugged capillary introducing the sample to 
the ionization source. The problem disappeared at in- 
jection 21. The concentrations measured at these two 
injections were considered valid because the drug lev- 
els determined were consistent with the trend evident 
in the brain ECF concentration-time profile. This sug- 
gests that the variability was in the mass spectrometer 
response and not due to sample processing. The use of 
the internal standard should compensate for this in- 
strument variability, thereby minimizing the impact 
on the accuracy of the measurements. Typically, if a 
large response difference is noticed in a sample analy- 
sis, the data are evaluated to determine if reanalysis is 
necessary. Following the analysis of hundreds of sam- 
ples via this method, we observed differences (> 20%) 
in the I.S. response (compared to the mean for the run> 
perhaps for 4% of the injections. Even with the large 
difference from the mean at injections 19 and 20, the 
relative standard deviation (%RSD) for the internal 
standard response detected in postdose study samples 
(n = 35) was 10.2%. The good precision determined 
for the I.S. response in the study samples suggests that 
little variability was introduced by the handling of the 
small volume samples. Therefore, in this study, the use 
of small volume samples did not negatively impact the 
precision of the measured analyte concentration. Simi- 
larly, the precision in the I.S. measurement from cali- 
bration curve or QC samples was determined. The 
RSD for these samples (n = 25) was found to be com- 
parable at 12.3%. The mean value calculated for the 
internal standard signal in the postdose samples was 
10.4% less than the mean value of the signal deter- 
mined from calibration samples. These data indicate 
that the actual volume of microdialysate introduced 
into the vial either by the microdialysis syringe pump 
(postdose samples) or introduced manually for the QC 
samples (via a pipetter) differed slightly. No attempt 
was made to introduce a correction factor in the analy- 
sis of microdialysis study samples to compensate for 
apparent slight difference in sample volume relative to 
the volume of calibration standards. 
10 15 20 25 30 35 
Injection Number 
Figure 6. The normalized response of I.S. as indicated by chr+ 
matographic peak area, plotted as a function of injection number 
for the analysis of microdialysis perfusate collected for IO-min 
intervals following administration of I in rats. The overall %RSD 
was 10.2%. The dotted lines represent a deviation from the mean 
of 10%. 
Application 
Administration of I elicits CNS effects in vivo, indicat- 
ing that the compound is able to penetrate the BBB. 
However, the extent to which I or an active metabolite 
II penetrates into the brain was unknown. Displayed in 
Figure 7 are the concentration-time profiles for I and II 
in both the brain ECF and plasma following a 5-mg/kg 
i.v. dose administered to a single rat. The brain ECF 
concentrations represent free drug, whereas the mea- 
surement of I and II in plasma represents the total 
drug concentration. Whereas the plasma protein 
binding of each compound is - 55% [38], com- 
parison of the area under the curve (AUC) ratio 
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Figure 7. Semilogarithmic plot of plasma and brain ECF con- 
centration time profiles for I and II following a 5-mg/kg i.v. dose 
administered to a rat. Note that the brain ECF concentrations 
represent the free concentration, whereas the plasma values rep- 
resent the total drug concentration in plasma. The dashed line 
indicates the LLQ of I and II in brain ECF when taking into 
account the recovery of the microdialysis probe. 
AUC@,,in)/AUC(plasma) for I and II will reflect on the 
relative ability of each compound to penetrate the BBB. 
The ratio of AUC~Lb,ain)/AUC~,,pl,,,,, in this study 
was 0.67, whereas this ratio for II was 0.16, indicating 
that I crosses the BBB more efficiently than II. The 
dashed line in Figure 7 indicates the LLQ of II in brain 
ECF after taking into account the recovery through the 
probe. Although there are some levels of II indicated in 
brain ECF which fall below the LLQ of the method, we 
show these concentrations in the time profile as the 
signal generated in the sample analysis was greater 
than that observed for blank perfusate sample. All of 
the concentrations depicted in Figure 7 for I in brain 
ECF and plasma, and for II in plasma are above the 
LLQ of the assay. A complete investigation into the 
CNS penetration of I and II following 5-mg/kg i.v. and 
50-mg/kg oral dosing by using in vivo microdialysis 
sampling in rats (n = 3) is the subject of another report 
WI. 
Conclusion 
Methods based on microbore LC-MS/MS for quantifi- 
cation of compounds I and II in both microdialysis 
perfusate and rate plasma are described. The LC- 
MS/MS conditions were identical for each method. No 
sample processing was required in the analysis of 
aCSF samples generated in the rat brain microdialysis 
studies. Each sample was injected directly onto the LC 
column following the addition of the I.S. solution via 
the autosampler. An LLQ of 500 pg/mL was achieved 
for I and II in aCSF, which corresponds to 2.7 ng/mL 
(I) and 2.2 ng/mL (II) in brain ECF when taking into 
account recovery of the microdialysis probe. For the 
plasma analysis, the compounds were extracted by a 
simple acetonitrile protein precipitation procedure. Al- 
though the extraction efficiency of I was quite high in 
plasma, the recovery of II is poor. Nevertheless, data 
from the analysis of QC samples (both perfusate and 
plasma) are presented that demonstrate acceptable 
precision and accuracy for the method. The overall 
precision of the microdialysis perfusate sample analy- 
sis is determined by examining the %RSD of the inter- 
nal standard response detected in study and calibra- 
tion samples, Similar %RSDs and mean values in the 
I.S. detector response validate the sample handling 
procedures. These methods have been used to verify 
that I, and to a lesser extent its active metabolite II, 
penetrate the BBB following administration of I to rats. 
Understanding how brain and plasma levels correlate 
in rats may prove useful in predicting the extent to 
which the drug penetrates the human brain based on 
plasma concentrations. 
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